Patent Application for Pyrazolylcarboxamide Compounds for Therapy

ChangeBridge: Patent Apps - Organic Chemistry (C07D)

Published September 12th, 2023

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260085073A1) for pyrazolylcarboxamide compounds and their use in therapy. The application details compounds that inhibit MALT1 and their potential treatment for proliferative, inflammatory, or autoimmune disorders.

View original document View source feed page

What changed

This document is a published patent application from the USPTO detailing novel pyrazolylcarboxamide compounds. The application, filed on September 12, 2023, and published as US20260085073A1, describes these compounds and their pharmaceutical compositions for inhibiting the MALT1 protein. The stated uses include the treatment of various disorders such as proliferative, inflammatory, and autoimmune conditions.

This filing represents a step in the patent process, not a final grant of a patent. For companies in the pharmaceutical or biotechnology sectors, this application may indicate potential new therapeutic avenues or competitive intellectual property. Compliance officers should note that this is an application, and its implications will depend on the patent's eventual grant and scope. No immediate compliance actions are required based solely on this publication.

Source document (simplified)

← USPTO Patent Applications

PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY

Application US20260085073A1 Kind: A1 Mar 26, 2026

Inventors

Kenneth G. Carson, Geraldine Cirillo Harriman, Arwel Lewis, Gabriele Fumagalli, Benjamin Paul Whittaker, Alison Jones, Robert Stuart Laurie Chapman, Maria Angel Palomero-Vazquez, Riccardo Guareschi, Christopher James Lock, James Henry Lewis, Antonio Dore, Alicia Jayne Carey

Abstract

The invention provides pyrazolylcarboxamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein I (MALT1), and their use in the treatment of a disease or condition, such as a proliferative disorder, inflammatory disorder, or autoimmune disorder.

CPC Classifications

C07D 495/04 A61K 31/4155 A61K 31/4439 A61K 31/444 A61K 31/4545 A61K 31/4709 A61K 31/4725 A61K 31/4745 A61K 31/498 A61K 31/4985 A61K 31/502 A61K 31/5025 A61K 31/517 A61K 31/519 A61K 31/5365 A61K 31/538 A61K 31/5383 A61K 31/551 C07B 59/002 C07D 401/12 C07D 401/14 C07D 403/12 C07D 405/14 C07D 409/14 C07D 413/14 C07D 417/14 C07D 471/04 C07D 487/04 C07D 491/044 C07D 491/048 C07D 498/04 C07D 513/04